163 related articles for article (PubMed ID: 19106613)
1. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.
Ciarapica R; Russo G; Verginelli F; Raimondi L; Donfrancesco A; Rota R; Giordano A
Cell Cycle; 2009 Jan; 8(1):172-5. PubMed ID: 19106613
[No Abstract] [Full Text] [Related]
2. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
[TBL] [Abstract][Full Text] [Related]
3. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.
Zhang B; Liu XX; He JR; Zhou CX; Guo M; He M; Li MF; Chen GQ; Zhao Q
Carcinogenesis; 2011 Jan; 32(1):2-9. PubMed ID: 20952513
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.
Alajez NM; Shi W; Hui AB; Bruce J; Lenarduzzi M; Ito E; Yue S; O'Sullivan B; Liu FF
Cell Death Dis; 2010 Oct; 1(10):e85. PubMed ID: 21368858
[TBL] [Abstract][Full Text] [Related]
5. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
[TBL] [Abstract][Full Text] [Related]
6. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y
Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer.
Friedman JM; Jones PA; Liang G
Cell Cycle; 2009 Aug; 8(15):2313-4. PubMed ID: 19625769
[No Abstract] [Full Text] [Related]
8. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
10. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
11. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2.
Esposito F; Tornincasa M; Pallante P; Federico A; Borbone E; Pierantoni GM; Fusco A
J Clin Endocrinol Metab; 2012 May; 97(5):E710-8. PubMed ID: 22399519
[TBL] [Abstract][Full Text] [Related]
13. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
Sander S; Bullinger L; Klapproth K; Fiedler K; Kestler HA; Barth TF; Möller P; Stilgenbauer S; Pollack JR; Wirth T
Blood; 2008 Nov; 112(10):4202-12. PubMed ID: 18713946
[TBL] [Abstract][Full Text] [Related]
14. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
16. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.
Friedman JM; Liang G; Liu CC; Wolff EM; Tsai YC; Ye W; Zhou X; Jones PA
Cancer Res; 2009 Mar; 69(6):2623-9. PubMed ID: 19258506
[TBL] [Abstract][Full Text] [Related]
17. [Recent advances on EZH2 in malignant tumors].
Li J; Fan QH
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):856-8. PubMed ID: 20193471
[No Abstract] [Full Text] [Related]
18. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.
Song QC; Shi ZB; Zhang YT; Ji L; Wang KZ; Duan DP; Dang XQ
Oncol Rep; 2014 Mar; 31(3):1263-70. PubMed ID: 24452597
[TBL] [Abstract][Full Text] [Related]
19. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
Bao B; Ali S; Banerjee S; Wang Z; Logna F; Azmi AS; Kong D; Ahmad A; Li Y; Padhye S; Sarkar FH
Cancer Res; 2012 Jan; 72(1):335-45. PubMed ID: 22108826
[TBL] [Abstract][Full Text] [Related]
20. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
